

Please complete this **entire** form and fax it to: **866-940-7328**. If you have questions, please call **800-310-6826**.
This form contains multiple pages. Please complete all pages to avoid a delay in our decision.
Allow at least 24 hours for review.

Section A – Member Information

First Name:	Last Name:	Member ID:
Address:		
City:	State:	ZIP Code:
Phone:	DOB:	Allergies:
Primary Insurance:	Policy #:	Group #:

Is the requested medication New or Continuation of Therapy? If continuation, list start date: _____
 Is this patient currently hospitalized? Yes No If recently discharged, list discharge date: _____

Section B - Provider Information

First Name:	Last Name:	M.D./D.O.
Address:	City:	State: ZIP code:
Phone:	Fax:	NPI #: Specialty:
Office Contact Name / Fax attention to:		

Section C - Medical Information

Medication:	Strength:
Directions for use:	Quantity:
Diagnosis (Please be specific & provide as much information as possible):	ICD-10 CODE:
Is this member pregnant? <input type="checkbox"/> Yes <input type="checkbox"/> No If yes, what is this member's due date? _____	

Section D – Previous Medication Trials

Medications	Strength	Directions	Dates of Therapy	Reason for failure / discontinuation

Section E – Additional information and Explanation of why preferred medications would not meet the patient's needs
Please refer to www.uhccommunityplan.com for a list of preferred alternatives

Member First name:	Member Last name:	Member DOB:
--------------------	-------------------	-------------

Clinical and Drug Specific Information

ALL REQUESTS:

- Does the patient have one of the following diagnoses? Yes No (check which apply)
 - Chronic moderate to severe plaque psoriasis Active psoriatic arthritis
 - Other. List diagnosis: _____

- Is the patient currently on Taltz therapy? Yes No (Check which apply)
 If yes, list start date: _____

- Will the patient receive Taltz in combination with **ANY** of the following: Yes No
 - Biologic DMARD [e.g., Humira (adalimumab), Cimzia (certolizumab), Simponi (golimumab), Cosentyx (secukinumab), Orencia (abatacept)]
 - Janus kinase inhibitor [e.g., Xeljanz (tofacitinib)]
 - Phosphodiesterase 4 (PDE4) inhibitor [e.g. Otezla (apremilast)]

- Does the patient have greater than or equal to 5% body surface area involvement, palmoplantar, facial, or genital involvement, or severe scalp psoriasis? Yes No

- Does the patient have a history of failure, contraindication, or intolerance to topical therapy with any of the following: Yes No (check all that apply)
 - Corticosteroids Vitamin D analogs Tazarotene Calcineurin inhibitors
 - Anthralin Coal tar
 (If yes, complete Section D above with medication information, including dose, date of trial, and reason for discontinuation)

- Does the patient have a history of failure, contraindication, or intolerance to systemic therapy of at least 3 months duration with methotrexate? Yes No
 (If yes, complete Section D above with medication information, including dose, date of trial, and reason for discontinuation)

- Does the patient have a history of failure, contraindication, or intolerance to either of the following preferred biologic medications? Yes No (check which apply) Humira (adalimumab) Enbrel (etanercept)
 (If yes, complete Section D above with medication information, including dose, date of trial, and reason for discontinuation)

Requests for CONTINUATION FOR THERAPY:

- Does the patient have a documented positive clinical response to Taltz therapy? Yes No
 If yes, list response: _____

Physician Signature: _____ **Date:** _____

Confidentiality Notice: This transmission contains confidential information belonging to the sender and UnitedHealthcare. This information is intended only for the use of UnitedHealthcare. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action involving the contents of this document is prohibited. If you have received this telecopy in error, please notify the sender immediately.

Website: uhcommunityplan.com